Informations:
Erreur:
ID
34251
Description
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01309945
Lien
https://clinicaltrials.gov/show/NCT01309945
Mots-clés
Versions (1)
- 16/01/2019 16/01/2019 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
16 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Depression NCT01309945
Eligibility Depression NCT01309945
- StudyEvent: Eligibility
Similar models
Eligibility Depression NCT01309945
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
patients must be able to understand the nature of the study, agree to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use.
boolean
ID.2
Item
patients with a diagnosis of major depressive disorder, currently experiencing a major depressive episode, as defined by diagnostic and statistical manual of mental disorders- fourth edition text revision(dsm iv tr) criteria. the current depressive episode must be > 8 weeks in duration and < 3 years duration.
boolean
ID.3
Item
in the current major depressive disorder (mdd) episode, patients should report a history of inadequate response to 1 - 3 adequate trials of antidepressant treatment.
boolean
ID.4
Item
patients must have a 17-item hamilton depression rating scale (ham-d17) total score =>18 at screening.
boolean
ID.5
Item
patients who report an inadequate response (less than 50% reduction in depressive symptom severity) to more than three adequate trials of antidepressant treatments during the current depressive episode.
boolean
ID.6
Item
patients who have failed duloxetine at an adequate dose and for an adequate duration in their current episode unless in the judgment of the investigator, the patient could benefit from the treatment with this medication.
boolean
ID.7
Item
patients whose only inadequate response to an antidepressant in the current major depressive episode (mde) is to an serotonin norepinephrine reuptake inhibitors (snri) (duloxetine, venlafaxine, desvenlafaxine or milnacipran).
boolean